News | April 28, 2023
Laurus Labs Q4 FY23 consolidated PAT drops to to Rs. 102.98 Cr
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Bridging the gap between histopathology and molecular pathology
The business and product range of Ipca and that of Unichem complements each others business and product range
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Stedycon Sted super-resolution fluorescence microscope
Kyndryl's multi-cloud management solution leverages AI-based, cloud-hosted models to provide real-time metrics, events, logs, and traces
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
Laurus Labs has announced that the USFDA completed inspection of the formulations manufacturing facility Unit-2, APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh.
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
Indira IVF integrates diagnostics services with a special focus on women & child care to increase accessibility for patients
Subscribe To Our Newsletter & Stay Updated
